An assessment of EGFR and HER2 inhibitors with structure activity relationship of fused pyrimidine derivatives for breast cancer: a brief review
- 9 May 2023
- journal article
- review article
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 42 (3) , 1564-1581
Abstract
Epidermal growth factor receptor (EGFR) and its subtype human epidermal growth factor receptor 2 (HER2) gets activated when its endogenous ligand(s) bind to its ATP binding site of target receptors. In breast cancer (BC), EGFR and HER2 are two proteins are overexpressed which leads to overexpression of cells proliferation and decreases cell death/apoptosis. Pyrimidine is one of the most widely studied heterocyclic scaffolds for EGFR as well as HER2 inhibition. We gather some remarkable results for fused-pyrimidine derivatives on various cancerous cell lines (in-vitro) and animal (in-vivo) evaluation to highlight their potency. The heterocyclic (five, six-membered, etc.) moieties which are coupled with pyrimidine moiety are potent against EGFR and HER2 inhibitions. Hence structure-activity relationship (SAR) plays important role in study of heterocyclic moiety along pyrimidine and effects of substituents, groups for increase or decrease in the cancerous activity and toxicity. By thoughtful of fused pyrimidines SAR study, it facilitates in receiving excellent overview of the compounds by concerning of efficacy and potential summary for future EGFR inhibitors. Furthermore, we studied the in-silico interactions of synthesized compounds to evaluate binding affinity towards the key amino acids.. Communicated by Ramaswamy H. SarmaKeywords
This publication has 55 references indexed in Scilit:
- Novel pyrimidopyrimidine derivatives for inhibition of cellular proliferation and motility induced by h-prune in breast cancerEuropean Journal of Medicinal Chemistry, 2012
- Design, Synthesis and Biological Evaluation of Novel Pyrimido[4,5-d]pyrimidine CDK2 Inhibitors as Anti-tumor AgentsScientia Pharmaceutica, 2011
- Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomesCancer, 2010
- Synthesis and evaluation of 2,7-diamino-thiazolo[4,5-d] pyrimidine analogues as anti-tumor epidermal growth factor receptor (EGFR) tyrosine kinase inhibitorsBioorganic & Medicinal Chemistry Letters, 2009
- Dual EGFR/ErbB-2 inhibitors from novel pyrrolidinyl-acetylenic thieno[3,2-d]pyrimidinesBioorganic & Medicinal Chemistry Letters, 2008
- Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activityExpert Opinion on Biological Therapy, 2007
- Synthesis of New 4‐Aryl‐isoxazolo[5,4‐d]pyrimidin‐6‐one(thione) and 4‐Aryl‐pyrazolo[3,4‐d]pyrimidin‐6‐one Derivatives of Potential Antihypertensive Activity.ChemInform, 2007
- Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancersInternational Journal of Cancer, 2006
- The discovery of receptor tyrosine kinases: targets for cancer therapyNature Reviews Cancer, 2004
- Elevated epidermal growth factor receptor gene copy number and expression in a squamous carcinoma cell line.Journal of Clinical Investigation, 1985